Heart disease is currently the leading cause of death in the United States. In 2022, COVID-19 was the fourth leading cause of death in the United States, accounting for almost six percent of all deaths that year. The leading causes of death worldwide are similar to those in the United States. However, diarrheal diseases and neonatal conditions are major causes of death worldwide, but are not among the leading causes in the United States. Instead, accidents and chronic liver disease have a larger impact in the United States.

Racial differences

In the United States, there exist slight differences in leading causes of death depending on race and ethnicity. For example, assault, or homicide, accounts for around three percent of all deaths among the Black population but is not even among the leading causes of death for other races and ethnicities. However, heart disease and cancer are still the leading causes of death for all races and ethnicities.

Leading causes of death among men vs women

Similarly, there are also differences in the leading causes of death in the U.S. between men and women. For example, among men, intentional self-harm accounts for around two percent of all deaths but is not among the leading causes of death among women. On the other hand, influenza and pneumonia account for more deaths among women than men.

In 2019, the leading causes of death worldwide were ischemic heart disease, stroke, and chronic obstructive pulmonary disease (COPD). That year, ischemic heart disease and stroke accounted for a combined ** percent of all deaths worldwide. Although the leading causes of death worldwide vary by region and country, heart disease is a consistent leading cause of death regardless of income, development, size, or location. Heart disease In 2019, around **** million people worldwide died from ischemic heart disease. In comparison, around **** million people died from lung cancer that year, while *** million died from diabetes. The countries with the highest rates of death due to heart attack and other ischemic heart diseases are Lithuania, Russia, and Slovakia. Although some risk factors for heart disease, such as age and genetics, are unmodifiable, the likelihood of developing heart disease can be greatly reduced through a healthy lifestyle. The biggest modifiable risk factors for heart disease include smoking, an unhealthy diet, being overweight, and a lack of exercise. In 2019, it was estimated that around *** million deaths worldwide due to ischemic heart disease could be attributed to smoking. The leading causes of death in the United States Just as it is the leading cause of death worldwide, heart disease is also the leading cause of death in the United States. In 2023, heart disease accounted for ** percent of all deaths in the United States. Cancer was the second leading cause of death in the U.S. that year, followed by accidents. As of 2023, the odds that a person in the United States will die from heart disease is * in *. However, rates of death due to heart disease have actually declined in the U.S. over the past couple decades. From 2000 to 2022, there was a *** percent decline in heart disease deaths. On the other hand, deaths from Alzheimer’s disease saw an increase of *** percent over this period. Alzheimer’s disease is currently the sixth leading cause of death in the United States, accounting for **** deaths per 100,000 population in 2023.

This dataset presents the age-adjusted death rates for the 10 leading causes of death in the United States beginning in 1999. Data are based on information from all resident death certificates filed in the 50 states and the District of Columbia using demographic and medical characteristics. Age-adjusted death rates (per 100,000 population) are based on the 2000 U.S. standard population. Populations used for computing death rates after 2010 are postcensal estimates based on the 2010 census, estimated as of July 1, 2010. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for non-census years before 2010 are revised using updated intercensal population estimates and may differ from rates previously published. Causes of death classified by the International Classification of Diseases, Tenth Revision (ICD–10) are ranked according to the number of deaths assigned to rankable causes. Cause of death statistics are based on the underlying cause of death. SOURCES CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov). REFERENCES National Center for Health Statistics. Vital statistics data available. Mortality multiple cause files. Hyattsville, MD: National Center for Health Statistics. Available from: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm. Murphy SL, Xu JQ, Kochanek KD, Curtin SC, and Arias E. Deaths: Final data for 2015. National vital statistics reports; vol 66. no. 6. Hyattsville, MD: National Center for Health Statistics. 2017. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_06.pdf.

From 2018 to 2023, heart disease and cancer accounted for the highest share of deaths in the United States. In 2020 and 2021, COVID-19 became the third leading cause of death, accounting for around 12 percent of all deaths in 2021. However, by 2023, COVID-19 was responsible for only 1.6 percent of deaths, making it the tenth leading cause of death. This statistic shows the distribution of the 10 leading causes of death in the United States from 2018 to 2023.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

In the United States, the leading causes of death among women are heart disease and cancer. Heart disease and cancer are similarly the leading causes of death among U.S. men. In 2022, heart disease accounted for **** percent of all deaths among women in the United States, while cancer accounted for **** percent of deaths. COVID-19 was the third leading cause of death among both men and women in 2020 and 2021, and the fourth leading cause in 2022. Cancer among women in the U.S. The most common types of cancer among U.S. women are breast, lung and bronchus, and colon and rectum. In 2025, there were around ******* new breast cancer cases among women, compared to ******* new cases of lung and bronchus cancer. Although breast cancer is the most common form of cancer among women in the United States, lung and bronchus cancer causes the highest number of cancer deaths. In 2025, around ****** women were expected to die from lung and bronchus cancer, compared to ****** from breast cancer. Breast cancer Although breast cancer is the second most deadly form of cancer among women, rates of death have decreased over the past few decades. This decrease is possibly due to early detection, progress in therapy, and increasing awareness of risk factors. In 2023, the death rate due to breast cancer was **** per 100,000 population, compared to a rate of **** per 100,000 in the year 1990. The state with the highest rate of deaths due to breast cancer is Oklahoma, while South Dakota had the lowest rates.

Historical chart and dataset showing U.S. death rate by year from 1950 to 2025.

This statistic shows the percentage changes in selected causes of death due to diseases in the United States, between 2000 and 2022. The number of deaths caused by prostate cancer increased by 7.4 percent during this period. Changes in selected causes of deathThere has been a decrease in the rate of death caused by many diseases, including stroke and heart disease. However, the mortality rate due to Alzheimer’s disease increased by 142 percent from 2000 to 2022. Alzheimer’s disease caused 27.7 deaths per 100,000 population in 2023, making it the sixth leading cause of death in the United States. Mortality rates due to different diseases vary by different factors, including race and ethnicity. For example, cancer is the leading cause of death among Asians and Pacific Islanders in the United States, accounting for 22 percent of total deaths among this population, while heart disease is the leading cause of death among the white population. Ischemic heart disease is the leading cause of death worldwide, accounting for around nine million deaths in 2021. In the early 1900's, the mortality rate was primarily concentrated among people of younger ages, but increasingly, this has shifted to older population groups. In recent years, decreased mortality rates are often linked to improved medical care, such as new developments in medical technologies. Shifts in lifestyle habits such as decreased smoking rates and healthier diets may also attribute to lower mortality rates.

Chronic Disease Management Market Outlook

The global chronic disease management market size was valued at USD 4.5 billion in 2023 and is projected to reach USD 9.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.1% during the forecast period. The increasing prevalence of chronic diseases such as cardiovascular diseases, diabetes, and cancer, coupled with the rising adoption of healthcare IT solutions, is driving the growth of this market. Chronic diseases are leading causes of mortality and morbidity worldwide, prompting healthcare providers and governments to invest heavily in management solutions to improve patient outcomes and reduce healthcare costs.

One of the primary growth factors propelling the chronic disease management market is the escalating burden of chronic diseases globally. With aging populations and lifestyle changes, conditions such as cardiovascular diseases, diabetes, and chronic respiratory diseases are becoming more prevalent. This surge in chronic diseases necessitates robust management solutions that can effectively monitor and manage patient health, thereby reducing hospital readmissions and improving quality of life. Innovations in telemedicine and remote monitoring technologies are also contributing to the market's expansion, enabling continuous patient care and timely interventions.

Technological advancements in healthcare IT is another significant driver of the chronic disease management market. The integration of artificial intelligence (AI) and machine learning algorithms in chronic disease management solutions is enhancing predictive analytics, enabling early diagnosis and personalized treatment plans. These technologies facilitate the collection and analysis of large volumes of patient data, providing healthcare providers with actionable insights to optimize care delivery. Furthermore, the adoption of electronic health records (EHR) and mobile health applications is streamlining patient management, improving communication between patients and healthcare professionals, and promoting patient engagement in their own health management.

Government initiatives and policies aimed at improving public health are also fueling the growth of the chronic disease management market. Many governments across the globe are implementing programs to promote preventive care and chronic disease management to reduce the financial burden on healthcare systems. These initiatives include funding for healthcare IT infrastructure, patient education programs, and reimbursement policies for chronic disease management services. Additionally, private sector investments in healthcare innovation and collaborations between technology companies and healthcare providers are further accelerating market growth.

Disease Registry Software plays a pivotal role in the chronic disease management landscape by providing a comprehensive platform for tracking and analyzing patient data. This software enables healthcare providers to maintain detailed records of patients with chronic conditions, facilitating better monitoring and management of their health. By integrating with electronic health records and other healthcare IT systems, Disease Registry Software offers a centralized repository of patient information, allowing for seamless access and sharing of data across different healthcare settings. This enhances the ability of healthcare professionals to deliver personalized care, track disease progression, and implement timely interventions. Moreover, the use of Disease Registry Software supports population health management initiatives by enabling the identification of trends and patterns in chronic disease prevalence, thereby informing public health strategies and resource allocation.

From a regional perspective, North America dominates the chronic disease management market due to its advanced healthcare infrastructure, high adoption of innovative technologies, and proactive government policies. Europe follows closely, driven by its strong focus on improving healthcare outcomes and reducing chronic disease incidence. The Asia Pacific region is witnessing rapid market growth, attributed to increasing healthcare investments, rising prevalence of chronic diseases, and growing awareness about disease management solutions. Latin America and the Middle East & Africa also present significant growth opportunities, driven by improving healthcare infrastructure and increasing government initiatives to combat ch

The leading cause of death in low-income countries worldwide in 2021 was lower respiratory infections, followed by stroke and ischemic heart disease. The death rate from lower respiratory infections that year was 59.4 deaths per 100,000 people. While the death rate from stroke was around 51.6 per 100,000 people. Many low-income countries suffer from health issues not seen in high-income countries, including infectious diseases, malnutrition and neonatal deaths, to name a few. Low-income countries worldwide Low-income countries are defined as those with per gross national incomes (GNI) per capita of 1,045 U.S. dollars or less. A majority of the world’s low-income countries are located in sub-Saharan Africa and South East Asia. Some of the lowest-income countries as of 2023 include Burundi, Sierra Leone, and South Sudan. Low-income countries have different health problems that lead to worse health outcomes. For example, Chad, Lesotho, and Nigeria have some of the lowest life expectancies on the planet. Health issues in low-income countries Low-income countries also tend to have higher rates of HIV/AIDS and other infectious diseases as a consequence of poor health infrastructure and a lack of qualified health workers. Eswatini, Lesotho, and South Africa have some of the highest rates of new HIV infections worldwide. Likewise, tuberculosis, a treatable condition that affects the respiratory system, has high incident rates in lower income countries. Other health issues can be affected by the income of a country as well, including maternal and infant mortality. In 2023, Afghanistan had one of the highest rates of infant mortality rates in the world.

Note: DPH is updating and streamlining the COVID-19 cases, deaths, and testing data. As of 6/27/2022, the data will be published in four tables instead of twelve.

The COVID-19 Cases, Deaths, and Tests by Day dataset contains cases and test data by date of sample submission. The death data are by date of death. This dataset is updated daily and contains information back to the beginning of the pandemic. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-Cases-Deaths-and-Tests-by-Day/g9vi-2ahj.

The COVID-19 State Metrics dataset contains over 93 columns of data. This dataset is updated daily and currently contains information starting June 21, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-State-Level-Data/qmgw-5kp6 .

The COVID-19 County Metrics dataset contains 25 columns of data. This dataset is updated daily and currently contains information starting June 16, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-County-Level-Data/ujiq-dy22 .

The COVID-19 Town Metrics dataset contains 16 columns of data. This dataset is updated daily and currently contains information starting June 16, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-Town-Level-Data/icxw-cada . To protect confidentiality, if a town has fewer than 5 cases or positive NAAT tests over the past 7 days, those data will be suppressed.

COVID-19 cases and associated deaths that have been reported among Connecticut residents, broken down by race and ethnicity. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. Deaths reported to the either the Office of the Chief Medical Examiner (OCME) or Department of Public Health (DPH) are included in the COVID-19 update.

The following data show the number of COVID-19 cases and associated deaths per 100,000 population by race and ethnicity. Crude rates represent the total cases or deaths per 100,000 people. Age-adjusted rates consider the age of the person at diagnosis or death when estimating the rate and use a standardized population to provide a fair comparison between population groups with different age distributions. Age-adjustment is important in Connecticut as the median age of among the non-Hispanic white population is 47 years, whereas it is 34 years among non-Hispanic blacks, and 29 years among Hispanics. Because most non-Hispanic white residents who died were over 75 years of age, the age-adjusted rates are lower than the unadjusted rates. In contrast, Hispanic residents who died tend to be younger than 75 years of age which results in higher age-adjusted rates.

The population data used to calculate rates is based on the CT DPH population statistics for 2019, which is available online here: https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Population-Statistics. Prior to 5/10/2021, the population estimates from 2018 were used.

Rates are standardized to the 2000 US Millions Standard population (data available here: https://seer.cancer.gov/stdpopulations/). Standardization was done using 19 age groups (0, 1-4, 5-9, 10-14, ..., 80-84, 85 years and older). More information about direct standardization for age adjustment is available here: https://www.cdc.gov/nchs/data/statnt/statnt06rv.pdf

Categories are mutually exclusive. The category “multiracial” includes people who answered ‘yes’ to more than one race category. Counts may not add up to total case counts as data on race and ethnicity may be missing. Age adjusted rates calculated only for groups with more than 20 deaths. Abbreviation: NH=Non-Hispanic.

Data on Connecticut deaths were obtained from the Connecticut Deaths Registry maintained by the DPH Office of Vital Records. Cause of death was determined by a death certifier (e.g., physician, APRN, medical examiner) using their best clinical judgment. Additionally, all COVID-19 deaths, including suspected or related, are required to be reported to OCME. On April 4, 2020, CT DPH and OCME released a joint memo to providers and facilities within Connecticut providing guidelines for certifying deaths due to COVID-19 that were consistent with the CDC’s guidelines and a reminder of the required reporting to OCME.25,26 As of July 1, 2021, OCME had reviewed every case reported and performed additional investigation on about one-third of reported deaths to better ascertain if COVID-19 did or did not cause or contribute to the death. Some of these investigations resulted in the OCME performing postmortem swabs for PCR testing on individuals whose deaths were suspected to be due to COVID-19, but antemortem diagnosis was unable to be made.31 The OCME issued or re-issued about 10% of COVID-19 death certificates and, when appropriate, removed COVID-19 from the death certificate. For standardization and tabulation of mortality statistics, written cause of death statements made by the certifiers on death certificates are sent to the National Center for Health Statistics (NCHS) at the CDC which assigns cause of death codes according to the International Causes of Disease 10th Revision (ICD-10) classification system.25,26 COVID-19 deaths in this report are defined as those for which the death certificate has an ICD-10 code of U07.1 as either a primary (underlying) or a contributing cause of death. More information on COVID-19 mortality can be found at the following link: https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Mortality/Mortality-Statistics

Data are subject to future revision as reporting changes.

Starting in July 2020, this dataset will be updated every weekday.

Additional notes: A delay in the data pull schedule occurred on 06/23/2020. Data from 06/22/2020 was processed on 06/23/2020 at 3:30 PM. The normal data cycle resumed with the data for 06/23/2020.

A network outage on 05/19/2020 resulted in a change in the data pull schedule. Data from 5/19/2020 was processed on 05/20/2020 at 12:00 PM. Data from 5/20/2020 was processed on 5/20/2020 8:30 PM. The normal data cycle resumed on 05/20/2020 with the 8:30 PM data pull. As a result of the network outage, the timestamp on the datasets on the Open Data Portal differ from the timestamp in DPH's daily PDF reports.

Starting 5/10/2021, the date field will represent the date this data was updated on data.ct.gov. Previously the date the data was pulled by DPH was listed, which typically coincided with the date before the data was published on data.ct.gov. This change was made to standardize the COVID-19 data sets on data.ct.gov.

This dataset contains counts of deaths for California counties based on information entered on death certificates. Final counts are derived from static data and include out-of-state deaths to California residents, whereas provisional counts are derived from incomplete and dynamic data. Provisional counts are based on the records available when the data was retrieved and may not represent all deaths that occurred during the time period. Deaths involving injuries from external or environmental forces, such as accidents, homicide and suicide, often require additional investigation that tends to delay certification of the cause and manner of death. This can result in significant under-reporting of these deaths in provisional data.

The final data tables include both deaths that occurred in each California county regardless of the place of residence (by occurrence) and deaths to residents of each California county (by residence), whereas the provisional data table only includes deaths that occurred in each county regardless of the place of residence (by occurrence). The data are reported as totals, as well as stratified by age, gender, race-ethnicity, and death place type. Deaths due to all causes (ALL) and selected underlying cause of death categories are provided. See temporal coverage for more information on which combinations are available for which years.

The cause of death categories are based solely on the underlying cause of death as coded by the International Classification of Diseases. The underlying cause of death is defined by the World Health Organization (WHO) as "the disease or injury which initiated the train of events leading directly to death, or the circumstances of the accident or violence which produced the fatal injury." It is a single value assigned to each death based on the details as entered on the death certificate. When more than one cause is listed, the order in which they are listed can affect which cause is coded as the underlying cause. This means that similar events could be coded with different underlying causes of death depending on variations in how they were entered. Consequently, while underlying cause of death provides a convenient comparison between cause of death categories, it may not capture the full impact of each cause of death as it does not always take into account all conditions contributing to the death.

The countries with the highest suicide mortality rate worldwide in 2019 included Lesotho, Guyana, and Eswatini. Suicide rates of men are much higher than among women in many countries. Lithuania has one of the highest suicide rates for men as of 2019, while South Korea reports the highest suicide rate for women.

In the United States

Although the United States is not among the countries with the highest suicide mortality rate, suicide is still one of the leading causes of death in the U.S. As with other countries, the suicide rate among males in the U.S. is much higher than among females. The age group with the highest rate of suicide is those aged 45 to 64 years, followed by 25 to 44-year-olds. The states with the highest suicide rates are Wyoming, Alaska, and Montana.

Risk factors and help

Major risk factors for suicide include mental health issues and substance abuse problems; however, it can be difficult to predict who is at risk. Warning signs such as talking about wanting to die, expressing feelings of depression, suicidal ideation, and abusing drugs or alcohol should be taken seriously and help should be sought as soon as possible. Suicide hotlines exist in many countries around the world and one should not hesitate to discuss such issues and feelings with a health care provider.

As of 2023, the countries with the highest death rates worldwide were Monaco, Bulgaria, and Latvia. In these countries, there were ** to ** deaths per 1,000 people. The country with the lowest death rate is Qatar, where there is just *** death per 1,000 people. Leading causes of death The leading causes of death worldwide are, by far, cardiovascular diseases, accounting for ** percent of all deaths in 2021. That year, there were **** million deaths worldwide from ischaemic heart disease and **** million from stroke. Interestingly, a worldwide survey from that year found that people greatly underestimate the proportion of deaths caused by cardiovascular disease, but overestimate the proportion of deaths caused by suicide, interpersonal violence, and substance use disorders. Death in the United States In 2023, there were around **** million deaths in the United States. The leading causes of death in the United States are currently heart disease and cancer, accounting for a combined ** percent of all deaths in 2023. Lung and bronchus cancer is the deadliest form of cancer worldwide, as well as in the United States. In the U.S. this form of cancer is predicted to cause around ****** deaths among men alone in the year 2025. Prostate cancer is the second-deadliest cancer for men in the U.S. while breast cancer is the second deadliest for women. In 2023, the tenth leading cause of death in the United States was COVID-19. Deaths due to COVID-19 resulted in a significant rise in the total number of deaths in the U.S. in 2020 and 2021 compared to 2019, and it was the third leading cause of death in the U.S. during those years.

In the United States in 2021, the death rate was highest among those aged 85 and over, with about 17,190.5 men and 14,914.5 women per 100,000 of the population passing away. For all ages, the death rate was at 1,118.2 per 100,000 of the population for males, and 970.8 per 100,000 of the population for women. The death rate Death rates generally are counted as the number of deaths per 1,000 or 100,000 of the population and include both deaths of natural and unnatural causes. The death rate in the United States had pretty much held steady since 1990 until it started to increase over the last decade, with the highest death rates recorded in recent years. While the birth rate in the United States has been decreasing, it is still currently higher than the death rate. Causes of death There are a myriad number of causes of death in the United States, but the most recent data shows the top three leading causes of death to be heart disease, cancers, and accidents. Heart disease was also the leading cause of death worldwide.

BackgroundCardiovascular diseases (CVDs) are not only the primary cause of mortality in China but also represent a significant financial burden. The World Health Organization highlight that as China undergoes rapid socioeconomic development, its disease spectrum is gradually shifting towards that of developed countries, with increasing prevalence of lifestyle-related diseases such as ischemic heart disease and stroke. We reviewed the rates and trends of CVDs incidence, mortality and disability-adjusted life years (DALYs) burden in China and compared them with those in the United States (US) and Japan for formulating CVDs control policies.MethodsData on CVDs incidence, death and DALYs in China, the US and Japan were obtained from the GBD 2019 database. The Joinpoint regression model was used to analyze the trends in CVDs incidence and mortality in China, the US and Japan, calculate the annual percentage change and determine the best-fitting inflection points.ResultsIn 2019, there were approximately 12,341,074 new diagnosed cases of CVDs in China, with 4,584,273 CVDs related deaths, causing 91,933,122 DALYs. The CVDs age-standardized incidence rate (ASIR) in China (538.10/100,000) was lower than that in the US and globally, while age-standardized death rate (ASDR) (276.9/100,000) and age-standardized DALY rate (6,463.47/100,000) were higher than those in the two regions. Compared with the US and Japan, from 1990 to 2019, the CVDs incidence rate in China showed an increasing trend, with a lower annual decrease in ASDR and a younger age structure of disease burden. Furthermore, the disease spectrum in China changed minimally, with stroke, ischemic heart disease, and hypertensive heart disease being the top three leading CVDs diseases in terms of incidence and disease burden, also being the major causes of CVDs in the US and Japan.ConclusionThe prevention and control of CVDs is a global issue. The aging population and increasing unhealthy lifestyles will continue to increase the burden in China. Therefore, relevant departments in China should reference the established practices for CVDs control in developed countries while considering the diversity of CVDs in different regions when adjusting national CVDs control programs.

breastcanc-ultrasound-class

  Background

Cancer is the second leading cause of death worldwide, according to IHME - Global Burden of Disease, with 10.7 mln casualties in 2019.

Amongst the various types of cancer, a huge role is played by breast cancer, which stands in 4th position among the deadliest tumors, with more than 700.000 deaths during 2019 (IHME - Global Burden of Disease).

Moreover, breast cancer has the highest share of number of cases/100 people worldwide… See the full description on the dataset page: https://huggingface.co/datasets/as-cle-bert/breastcanc-ultrasound-class.

It is estimated that alcohol contributes to around three million deaths worldwide per year. That is about five percent of all deaths each year. The major causes of alcohol-related death include alcohol poisoning, liver damage, heart failure, cancer, and car accidents.

Alcohol abuse worldwide Despite the widespread use of alcohol around the world, a global survey from 2021 of people from 30 different countries, found that around 11 percent of respondents stated alcohol abuse was the biggest health problem facing people in their country. It is currently estimated that around 1.38 percent of the global population has alcohol use disorder, however binge drinking and excessive alcohol use, both of which carry health risks, are much more common. The countries with the highest per capita consumption of alcohol include Czechia, Latvia, and the Republic of Moldova.

Alcohol consumption in the United States It is estimated that around 60 percent of adults in the United States aged 21 to 49 years currently use alcohol. Binge drinking (four or more drinks for women and five or more drinks for men on a single occasion) is most common among those aged 21 to 25 years, but still around 29 percent of those aged 40 to 44 report binge drinking. The states with the highest share of the population who binge drink are Wisconsin, North Dakota, and Montana. The death rate due to alcohol in the United States was around 13 per 100,000 population in 2020, an increase from a rate of 10.4 per 100,000 recorded in 2019.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

Overview

New York, NY – May 27, 2025 – Global Cancer Therapeutics and Biotherapeutics Market size is expected to be worth around US$ 417.2 Billion by 2034 from US$ 184.5 Billion in 2024, growing at a CAGR of 8.5% during the forecast period 2025 to 2034.

The global cancer therapeutics and biotherapeutics market is undergoing rapid transformation, driven by continuous innovations in immunotherapy, targeted drug delivery, and cell-based therapies. With cancer remaining one of the leading causes of death worldwide, the demand for effective, personalized, and minimally invasive treatment options is steadily rising. According to data from the World Health Organization (WHO), cancer accounted for nearly 10 million deaths globally in 2022, underscoring the urgent need for advanced therapeutic solutions.

Biotherapeutics such as monoclonal antibodies, CAR-T cell therapy, and immune checkpoint inhibitors are significantly improving patient outcomes, particularly in treating hematologic malignancies and solid tumors. These therapies are increasingly being integrated into first-line treatment regimens across various cancer types, including breast, lung, and colorectal cancers.

Pharmaceutical companies and research institutes are investing heavily in clinical trials and regulatory approvals. The U.S. Food and Drug Administration (FDA) has accelerated the approval of several biologics under its breakthrough therapy and fast track designations, facilitating faster patient access to novel treatments.

North America currently dominates the market due to a strong healthcare infrastructure and high R&D investments, while Asia-Pacific is projected to witness the fastest growth owing to rising cancer incidence and healthcare reforms.